International Lung Cancer Congress | Conference

Combinations, Ex Vivo Manipulation May Be Key to Enhancing T-Cell Activity in Lung Cancer

July 30th 2022

Roy S. Herbst, MD, PhD, discusses the importance of evaluating ways of altering tumor host factors to improve response to immunotherapy in patients with lung cancer.

Dr. Morgensztern on Advances With Amivantamab in NSCLC

July 30th 2022

Daniel Morgensztern, MD, discusses ongoing research with amivantamab-vmjw in non–small cell lung cancer.

Dr. Bazhenova on Larotrectinib and Entrectinib in NTRK Fusion–Positive NSCLC

July 30th 2022

Lyudmila A. Bazhenova, MD, discusses NTRK inhibition with larotrectinib and entrectinib in patients with NTRK fusion–positive non–small cell lung cancer.

Bispecific Antibodies and BiTEs Under Continued Evaluation in Lung Cancer

July 30th 2022

Daniel Morgensztern, MD, discusses updates on the investigation of bispecific antibodies and bispecific T-cell engagers in non–small cell lung cancer and small cell lung cancer.

Glutaminase Inhibition Represents Novel Treatment Strategy in NFE2L2- and KEAP1-Mutated NSCLC

July 30th 2022

Jonathan Wesley Riess, MD, MS, discusses a phase 1 trial examining the combination of sapanisertib and telaglenastat, and explains why glutaminase inhibition is being investigated as a novel way to treat select patients with non–small cell lung cancer.

EGFR TKI–Based Combos Could Lead to More Tailored First-Line Treatment Options in EGFR-Mutated NSCLC

July 29th 2022

Leveraging EGFR TKIs as a backbone for combination therapies will be pivotal for expanding treatment options and delivering more personalized therapies in the first-line setting for patients with non–small cell lung cancer harboring EGFR mutations.

Novel Biomarker Testing Could Enhance Immunotherapy Treatment Decisions in NSCLC

July 29th 2022

PD-L1 and tumor mutational burden are established biomarkers for leveraging immunotherapy in non–small cell lung cancer; however, their use may not be appropriate in determining treatment decisions for all patients.

Investigators Set Sights on Resistance Following Establishment of Frontline RET Inhibition in RET-Altered NSCLC

July 29th 2022

With two highly selective and active RET inhibitors approved for use in patients with metastatic RET alteration–positive non–small cell lung cancer, the dilemma is not determining which agent to select but ensuring that next-generation sequencing is done up front and in the presence of acquired resistance.

Dr. Baas on Immunotherapy in Mesothelioma Subpopulations

July 29th 2022

Paul Baas, MD, PhD, discusses the benefits of immunotherapy in subpopulations of patients with mesothelioma. 

Dr. Reckamp on Treatment Decisions in MET Exon 14–Mutated NSCLC

July 29th 2022

Karen Reckamp, MD, compares capmatinib and tepotinib, 2 drugs that are approved for the treatment of MET exon 14–mutated non–small cell lung cancer.

HER2-Mutated NSCLC Treatment Evolves From Mainstay TKIs to Novel ADCs and Beyond

July 29th 2022

Antibody-drug conjugates have demonstrated substantial activity in patients with HER2-mutated non–small cell lung cancer, with fam-trastuzumab deruxtecan-nxki showcasing the strongest response rate and progression-free survival benefit to date.

Addressing Disparities in Lung Cancer Begins With Accountability

July 28th 2022

Narjust Florez (Duma), MD, discusses the alarming regularity of disparities in lung cancer care, the elements that perpetuate them, and ways to address them on an individual and institutional level.

Dr. Gandara on the Evaluation of Tumor Biomarkers in NSCLC

July 28th 2022

David R. Gandara, MD, discusses the evaluation of tumor biomarkers in non–small cell lung cancer.

Dr. Massarelli on Unmet Needs in EGFR Exon 20–Mutated NSCLC

July 28th 2022

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in EGFR exon 20–mutated non–small cell lung cancer.

Value of Biomarkers for Immunotherapy in Advanced NSCLC Continue to Evolve

July 28th 2022

Traditional predictive biomarkers for the efficacy of peri-operative immunotherapy for patients with advanced non–small cell lung cancer, such as PD-L1 expression, still hold value but newer biomarker candidates such as minimal residual disease are starting to make an impact.

Pathology Expert Unpacks the Future Role MPR and pCR in Neoadjuvant NSCLC Treatment

July 28th 2022

Ignacio I. Wistuba, MD, explains how major pathological response and pathological complete response should be interpreted and their role as clinical end points.

MRD Status Alone Is Not Necessarily Predictive of Response to Immunotherapy in NSCLC

July 28th 2022

Thought minimal residual disease can serve as an indicator for poor outcomes for patients with non–small cell lung cancer, it is not necessarily a predictor of response to immunotherapy.

Dr. Kelly on Overcoming Osimertinib Resistance in NSCLC With Bispecific Antibodies

August 1st 2021

Karen L. Kelly, MD, discusses overcoming osimertinib resistance in patients with non–small cell lung cancer through the use of bispecific antibodies.

Dr. Reckamp on the Significance of ALTA in ALK+ NSCLC

August 1st 2021

Karen L. Reckamp, MD, discusses the significance of the final results of the ALTA trial in patients with ALK-positive non–small cell lung cancer.

Research Efforts Seek to Unlock the Potential of PARP Inhibition in Thoracic Malignancies

August 1st 2021

Ongoing studies with biomarker-selected cohorts may help to identify subsets of patients with thoracic malignancies who might confer benefit from PARP inhibitors.